Abstract:Background Currently approved CAR-T cells primarily utilize retroviral or lentiviral vectors (LV), posing significant challenges due to their time-consuming and costly nature, and associated safety concerns, including insertional mutagenesis. Consequently, mRNA delivery holds promising prospects in CAR-T cell engineering. AXL represents an ideal target for LV-engineered CAR-T cells in the treatment of various malignancies, including breast, lung, and pancreatic cancer. However, the anti-tumor activity of mRNA-based AXL CAR-T cells remains to be fully elucidated. Methods We developed a novel CAR utilizing a fully humanized AXL-specific antibody. Subsequently, the mRNA encoding AXL-specific CAR was synthesized via in vitro transcription. This mRNA was then transfected into pre-activated T cells through electroporation. The expression levels of mRNA-based CAR were evaluated by flow cytometry. Furthermore, in vitro and in vivo assays were performed to evaluate the antigen-specific cytotoxicity and cytokine release capabilities of mRNA-based AXL CAR-T cells in various tumor cells and in a tumor-bearing mouse model. Results Electroporation of mRNA-encoding AXL CAR minimally affected T cell viability, resulting in high CAR expression over 90%, and this CAR expression persisted for at least three days following electroporation, consistent with observed cytotoxicity against the lung cancer cell line A549. mRNA-based AXL CAR-T cells exhibited dose-dependent cytotoxicity against both A549 and pancreatic cancer cell line Panc-1, achieving a killing rate exceeding 80% at an effector:target ratio of 4:1. Additionally, mRNA-based AXL CAR-T cells specifically secreted high level of cytokines IL-2 and IFN-γ upon interaction with target tumor cells. mRNA-based AXL CAR-T cells exhibited minimal impact on T cell subtypes while demonstrating robust cytotoxicity comparable to LV-engineered CAR-T cells. Additionally, mRNA-based AXL CAR-T cells demonstrated good anti-tumor activity in a subcutaneous lung cancer xenograft model. Conclusions mRNA-based AXL CAR-T cells transiently expressed high levels of CAR, enabling cost-effective large-scale production, and comparable functionality to LV-engineered CAR-T cells within a short time frame, which offers a safe alternative for clinical therapy utilizing LV-engineered CAR-T cells. mRNA-based AXL CAR-T cells have shown promising results in treating solid tumors, including lung cancer and pancreatic cancer, establishing an experimental basis for their potential clinical application in solid tumors.

A novel AXL chimeric antigen receptor endows T cells with anti-tumor effects against triple negative breast cancers

Use of AXL-specific CAR T cells to treat non-small-cell lung cancer

Abstract LB342: Potent Anti-Tumor Activity Demonstrated by Anti-AXL CAR T Cell Therapy and AXL-ADC in Lung Cancer and Breast Cancer Models

Mrna-Based AXL-targeting Chimeric Antigen Receptor-T Cells Against Solid Tumors

Intercellular Adhesion Molecule-1 as Target for CAR-T-Cell Therapy of Triple-Negative Breast Cancer

Novel chimeric antigen receptor T cell-based immunotherapy: a perspective for triple-negative breast cancer

Chimeric Antigen Receptor-Modified T Cells Redirected to EphA2 for the Immunotherapy of Non-Small Cell Lung Cancer

Antitumor effect of CAR-T cells targeting transmembrane tumor necrosis factor alpha combined with PD-1 mAb on breast cancers

AXL inhibition improves the anti-tumor activity of chimeric antigen receptor T cells.

Remodelling of tumour microenvironment by microwave ablation potentiates immunotherapy of AXL-specific CAR T cells against non-small cell lung cancer

AXL antibody and AXL-ADC mediate antitumor efficacy via targeting AXL in tumor-intrinsic epithelial-mesenchymal transition and tumor-associated M2-like macrophage

A Novel CAR Design Showing a Favorable Risk to Potency Ratio for the Treatment of Triple Negative Breast Cancer

CAR T-cell therapy for triple-negative breast cancer: Where we are

EGFR-specific CAR-T cells trigger cell lysis in EGFR-positive TNBC

CD24 is a Novel Target of Chimeric Antigen Receptor T Cells for the Treatment of Triple Negative Breast Cancer

Self-reinforcing Nano-Spearhead Drives the Efficacy of CAR-T Cells Against Progressive Triple Negative Breast Cancer

EGFR‐targeted CAR‐T Cells Are Potent and Specific in Suppressing Triple‐negative Breast Cancer Both in Vitro and in Vivo

Tissue factor as a new target for CAR-NK cell immunotherapy of triple-negative breast cancer

Mesothelin-targeted CAR-NK Cells Derived From Induced Pluripotent Stem Cells Have a High Efficacy in Killing Triple-negative Breast Cancer Cells as Shown in Several Preclinical Models

Highly proliferative and hypodifferentiated CAR-T cells targeting B7–H3 enhance antitumor activity against ovarian and triple-negative breast cancers

CAR-T cell therapy for triple-negative breast cancer and other solid tumors: preclinical and clinical progress